Cargando…
Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)
Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical potency of hMSCs is based upon an initial direct hMSC effect on the pro-inflammatory and anti-microbial pathophysiology as well as...
Autores principales: | Bonfield, Tracey L., Sutton, Morgan T., Fletcher, David R., Reese-Koc, Jane, Roesch, Erica A., Lazarus, Hillard M., Chmiel, James F., Caplan, Arnold I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960767/ https://www.ncbi.nlm.nih.gov/pubmed/37259368 http://dx.doi.org/10.3390/ph16020220 |
Ejemplares similares
-
Expansion and Harvesting of hMSC-TERT
por: Weber, Christian, et al.
Publicado: (2007) -
Donor‐defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium
por: Bonfield, Tracey L., et al.
Publicado: (2021) -
BMP2 induces hMSC osteogenesis and matrix remodeling
por: Cai, Hantao, et al.
Publicado: (2021) -
Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment
por: Sutton, Morgan T., et al.
Publicado: (2016) -
Implementation of soft microfingers for a hMSC aggregate manipulation system
por: Konishi, Satoshi, et al.
Publicado: (2016)